-
Dr.HongzhouLu: NAD Management is Key for HIV Patients, Not Just Changing Medication
The use of highly active antiretroviral therapy (HAART) has led to effective virological control in HIV-infected individuals, significantly reducing mortality rates and transforming AIDS into a treatable and manageable chronic disease. Today, one of the main clinical challenges is how to choose more “efficient and less toxic” treatment options to improve patients’ quality of life.…
-
Challenges in HIV Management: Enhancing the Quality of Life for Elderly PLWH, Policy Interventions are Imperative
From July 23-26, 2023, the 12th International AIDS Society HIV Science Conference (IAS 2023) was held in Brisbane, Australia. In recent years, with the continuous advancement of modern antiretroviral therapy (ART), the life expectancy of people living with HIV (PLWH) has significantly improved. However, the accompanying aging issue of PLWH is becoming increasingly prominent, posing…
-
Dr. WeipingCai: Long-Acting Antiretroviral Drugs Usher in a New Chapter in AIDS Care
AIDS remains one of the most significant public health issues worldwide, with around 38 million people living with HIV (PLWH). In recent years, with the continuous advancement of antiretroviral therapy (ART), AIDS has gradually transformed into a manageable chronic disease. However, PLWH still face challenges like poor drug adherence and increased risk of resistance.
-
SGBCC 2023 Expert Voting: Surgical Treatment
The 18th St. Gallen International Breast Cancer Conference (SGBCC 2023) took place in Vienna, the “City of Music,” from March 15th to 18th, 2023. SGBCC gathered breast cancer opinion leaders from around the world to discuss and vote on the latest and most controversial topics in early breast cancer diagnosis and treatment, culminating in the…
-
2023 SGBCC Expert Voting: Early Treatment Decisions for Triple-Negative Breast Cancer
The 18th St. Gallen International Breast Cancer Conference (SGBCC 2023) was held in Vienna, the “City of Music,” from March 15 to 18, 2023. SGBCC brought together breast cancer opinion leaders from around the world to discuss and vote on the most cutting-edge and controversial topics in the diagnosis and treatment of early-stage breast cancer.…
-
SGBCC International Dialogue | Dr. JianZhang Discusses with Dr. Harbeck: Is Chemotherapy Necessary for ER+/HER2- Breast Cancer Patients with Low Genetic Risk but High Clinical Risk?
The 18th St. Gallen International Breast Cancer Conference (SG-BCC 2023) was held in Vienna, the “City of Music,” from March 15 to 18, 2023. Breast cancer experts from around the world gathered at this conference to discuss the most cutting-edge and controversial topics in the diagnosis and treatment of early-stage breast cancer, leading to the…
-
SGBCC 2023 | Academician BingheXu: Breast Cancer Treatment and Research – An Asian Perspective
The 18th St.Gallen International Breast Cancer Conference (SG-BCC 2023) was held in Vienna, the “City of Music,” from March 15 to 18, 2023. Academician Binghe Xu from the Cancer Hospital of the Chinese Academy of Medical Sciences delivered a presentation titled “Breast Cancer Treatment and Research – An Asian Perspective” during the “Session 10: Global Perspective…
-
SGBCC International Dialogue|Dr. LiZhu & Dr. Giuseppe Curigliano Discuss the Need for Adjuvant Therapy After Achieving pCR in Neoadjuvant Treatment
Neoadjuvant therapy has become an integral part of breast cancer treatment, with its increasing application in clinical practice. However, improving the effectiveness of neoadjuvant therapy and optimizing subsequent treatment strategies is a complex issue to consider. At the 18th St.Gallen Breast Cancer Conference (SGBCC 2023), a debate titled “If you achieve pCR after neoadjuvant, do…
Connecting Medical Expertise through Media